Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, has announced it will release its fourth quarter and full year 2024 financial results before market opening on Tuesday, March 11th.
Following the release, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can register to access the dial-in numbers with Conference ID: 73242.
A live webcast and replay of the conference call will be available on the company's investor relations website and through the provided event link.
Agenus Inc. (Nasdaq: AGEN), un leader nello sviluppo di nuovi agenti immunologici per il trattamento di vari tipi di cancro, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato il martedì 11 marzo.
Dopo il rilascio, i dirigenti di Agenus terranno una conference call e un webcast alle 8:30 a.m. ET per discutere i risultati e fornire un aggiornamento aziendale. Le parti interessate possono registrarsi per accedere ai numeri di telefono con ID Conferenza: 73242.
Un webcast dal vivo e la registrazione della conference call saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda e attraverso il link fornito per l'evento.
Agenus Inc. (Nasdaq: AGEN), un líder en el desarrollo de nuevos agentes inmunológicos para tratar varios tipos de cáncer, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el martes 11 de marzo.
Después de la publicación, los ejecutivos de Agenus llevarán a cabo una llamada de conferencia y un webcast a las 8:30 a.m. ET para discutir los resultados y proporcionar una actualización corporativa. Las partes interesadas pueden registrarse para acceder a los números de marcación con ID de Conferencia: 73242.
Un webcast en vivo y la repetición de la llamada de conferencia estarán disponibles en el sitio web de relaciones con inversores de la empresa y a través del enlace del evento proporcionado.
Agenus Inc. (Nasdaq: AGEN)는 다양한 암 치료를 위한 새로운 면역학적 제제를 개발하는 선도 기업으로, 2024년 4분기 및 연간 재무 결과를 3월 11일 화요일 시장 개장 전에 발표할 것이라고 발표했습니다.
발표 후, Agenus 경영진은 오전 8시 30분 ET에 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 진행합니다. 관심 있는 당사자는 회의 ID: 73242로 전화 접속 번호에 접근하기 위해 등록할 수 있습니다.
실시간 웹캐스트와 컨퍼런스 콜 재생은 회사의 투자자 관계 웹사이트 및 제공된 이벤트 링크를 통해 이용할 수 있습니다.
Agenus Inc. (Nasdaq: AGEN), un leader dans le développement de nouveaux agents immunologiques pour traiter divers cancers, a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année 2024 avant l'ouverture du marché le mardi 11 mars.
Après la publication, les dirigeants d'Agenus organiseront une conférence téléphonique et un webinaire à 8h30 ET pour discuter des résultats et fournir une mise à jour de l'entreprise. Les parties intéressées peuvent s'inscrire pour accéder aux numéros de composition avec l'ID de conférence : 73242.
Un webinaire en direct et un replay de la conférence téléphonique seront disponibles sur le site Web des relations avec les investisseurs de l'entreprise et via le lien de l'événement fourni.
Agenus Inc. (Nasdaq: AGEN), ein führendes Unternehmen in der Entwicklung neuartiger immunologischer Mittel zur Behandlung verschiedener Krebsarten, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 vor Markteröffnung am Dienstag, den 11. März veröffentlichen wird.
Nach der Veröffentlichung werden die Führungskräfte von Agenus um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Interessierte Parteien können sich registrieren, um Zugang zu den Einwahlnummern mit Konferenz-ID: 73242 zu erhalten.
Ein Live-Webcast und die Wiederholung der Telefonkonferenz werden auf der Website der Investor Relations des Unternehmens und über den bereitgestellten Veranstaltungslink verfügbar sein.
- None.
- None.
Conference Call:
To access dial-in numbers, please register here.
Conference ID: 73242
A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225538702/en/
Investors
917-362-1370
investor@agenusbio.com
Media
510-323-5188
communications@agenusbio.com
Source: Agenus Inc.
FAQ
When will Agenus (AGEN) release its Q4 and full year 2024 financial results?
What time is the AGEN earnings call scheduled for March 11th?
How can investors access Agenus (AGEN) Q4 2024 earnings call?
What is Agenus' (AGEN) primary business focus according to their latest announcement?
Will Agenus (AGEN) provide a corporate update during their March 2024 earnings call?
